Exjade (ICL 670): A new oral iron chelator.
ICL670(deferasirox) is a tridentate oral iron chelator that has shown high efficacy and theraputic safety in preclinical and currently ongoing phase III clinical evaluation. The drug has been just approved by US FDA for use in iron-loading anaemias. It is an ideal once-daily oral chelator, the effective dose of which is between 20 and 40 mg/kg. Iron is chelated & excreted almost exclusively via the feces. This is a major advance in the field of iron chelation.
Agarwal
M B
MB
Department of Haematology, Bombay Hospital Institute of Medical Sciences, Marine Lines, Mumbai 400 020.
D000284:Administration, Oral; D001565:Benzoates / Q000494:pharmacology* / Q000627:therapeutic use; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008961:Models, Structural; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox